Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ARQT 
Arcutis Biotherapeutics Inc (ARQT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ARQT (5-star) is a REGULAR-BUY. BUY since 17 days. Profits (4.17%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 58.85% | Avg. Invested days 31 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.78B USD | Price to earnings Ratio - | 1Y Target Price 20.25 |
Price to earnings Ratio - | 1Y Target Price 20.25 | ||
Volume (30-day avg) 2487515 | Beta 1.49 | 52 Weeks Range 6.99 - 17.75 | Updated Date 04/1/2025 |
52 Weeks Range 6.99 - 17.75 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -71.25% | Operating Margin (TTM) -10.7% |
Management Effectiveness
Return on Assets (TTM) -23.25% | Return on Equity (TTM) -113.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1736945613 | Price to Sales(TTM) 9.04 |
Enterprise Value 1736945613 | Price to Sales(TTM) 9.04 | ||
Enterprise Value to Revenue 8.84 | Enterprise Value to EBITDA -2.04 | Shares Outstanding 118638000 | Shares Floating 85249877 |
Shares Outstanding 118638000 | Shares Floating 85249877 | ||
Percent Insiders 2.02 | Percent Institutions 112.07 |
Analyst Ratings
Rating 4.38 | Target Price 19.12 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Arcutis Biotherapeutics Inc
Company Overview
History and Background
Arcutis Biotherapeutics, Inc. was founded in 2016. It is a commercial-stage biopharmaceutical company focused on developing and commercializing novel treatments for immune-mediated dermatological diseases.
Core Business Areas
- Medical Dermatology: Focuses on developing and commercializing treatments for chronic skin conditions like psoriasis, eczema, and vitiligo.
Leadership and Structure
Todd Simpson is the CEO. The company has a typical biopharmaceutical organizational structure with departments for research, development, commercialization, and administration.
Top Products and Market Share
Key Offerings
- ZORYVE (roflumilast) Topical Cream: A PDE4 inhibitor approved for plaque psoriasis. While specific market share data fluctuates, ZORYVE is a competitor to topical corticosteroids and other non-steroidal treatments. Competitors include: LEO Pharma (Enstilar), Incyte (Opzelura), and various generic topical corticosteroids.
- ZORYVE (roflumilast) Foam: A PDE4 inhibitor approved for seborrheic dermatitis. Competitors include: Sebclair, Ketoconazole, Ciclopirox.
Market Dynamics
Industry Overview
The dermatology market is growing, driven by an aging population, increasing awareness of skin conditions, and the availability of new treatments.
Positioning
Arcutis is positioned as an innovator in medical dermatology, focusing on novel topical treatments with differentiated mechanisms of action.
Total Addressable Market (TAM)
The global dermatology market is estimated to be worth billions of dollars. Arcutis targets specific segments within this market, like plaque psoriasis and seborrheic dermatitis, and seeks to capture a significant share with its novel therapies.
Upturn SWOT Analysis
Strengths
- Novel pipeline of topical treatments
- Approved products (ZORYVE)
- Experienced management team
- Strong intellectual property
Weaknesses
- Limited commercial history
- Reliance on key products
- Competition from established players
- Cash burn rate
Opportunities
- Expansion of ZORYVE indications
- Development of new products in dermatology
- Strategic partnerships
- Acquisition opportunities
Threats
- Regulatory hurdles
- Clinical trial failures
- Generic competition
- Pricing pressures
Competitors and Market Share
Key Competitors
- LLY
- BMY
- MRK
- INCY
Competitive Landscape
Arcutis faces competition from large pharmaceutical companies with established dermatology portfolios. Arcutis's advantage lies in its novel topical treatments and focus on specific patient populations.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Arcutis has experienced rapid revenue growth since the launch of ZORYVE.
Future Projections: Analysts project continued revenue growth driven by ZORYVE sales and potential approvals for additional indications.
Recent Initiatives: Arcutis is focused on expanding the label for ZORYVE and advancing its pipeline of other dermatology products.
Summary
Arcutis Biotherapeutics is a promising company in the dermatology space with an approved product. Its success hinges on expanding ZORYVE's market share and developing new products. The company is still operating at a loss and must manage its cash burn effectively. Future clinical trial results and regulatory decisions will be crucial for its long-term growth.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
INCY
Incyte Corporation
INCY
Incyte Corporation
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary based on source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcutis Biotherapeutics Inc
Exchange NASDAQ | Headquaters Westlake Village, CA, United States | ||
IPO Launch date 2020-01-31 | President, CEO & Director Mr. Todd Franklin Watanabe M.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 342 | Website https://www.arcutis.com |
Full time employees 342 | Website https://www.arcutis.com | ||
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.